Project Grant K08CA304362
Award Date 9/2/26
Completion Date 8/31/31
Dollars Obligated $283K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Memphis, TN 38105, USA
Similar Awards
- The National Cancer Institute awarded ST Jude Children's Research Hospital Inc. $737,023 under the Cancer Treatment Research program (CFDA 93.395) on July 23, 2026, to develop and evaluate CD19-CAR T cell therapy combined with TCR alpha/beta–depleted haploidentical hematopoietic cell transplantation for pediatric patients with relapsed or refractory CD19+ acute lymphoblastic leukemia and lymphoma. The research aims to minimize relapse risk and graft-versus-host disease while eliminating total...
- The National Cancer Institute awarded ST Jude Children's Research Hospital Inc. $143,814 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research training and career development in cancer biology. The award funds a K99 career transition award (Project Grant K99CA312755) focused on reprogramming chemoresistant cell states in high-risk neuroblastoma. The research addresses acquired drug resistance in pediatric cancer by investigating how neuroblastoma...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $263,656 on August 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research into novel mechanisms of acute myeloid leukemia (AML) resistance to chimeric antigen receptor T cell (CAR-T) therapy. The research aims to develop a detailed understanding of how altered STAT5 levels dictate poor outcomes for AML CAR-T therapies and to identify a combination therapy that selectively blocks AML...
- The National Cancer Institute (NCI), part of the Department of Health and Human Services, awarded $628,073 to St. Jude Children's Research Hospital Inc. on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to mechanistically dissect and target non-cell autonomous tumor promotion in DICER1 cancer predisposition. The project investigates how germline heterozygous loss-of-function mutations in DICER1, a ribonuclease III enzyme essential for processing microRNAs, drive...
- The National Cancer Institute awarded ST Jude Children's Research Hospital Inc. $491,925 under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, to develop machine learning methods for estimating personal symptom networks in childhood cancer survivors. The project applies interpretable machine learning to estimate individual-level symptom networks that incorporate cancer therapy history, genetic profile, demographics, socioeconomic status, lifestyle factors, and...
- The National Cancer Institute awarded ST Jude Children's Research Hospital Inc. $647,502 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small-molecule inhibitors targeting DDX19A as a novel anti-cancer therapeutic in Ewing sarcoma. The research examines DDX19A as a genomic dependency in Ewing sarcoma, an aggressive bone malignancy driven by the EWSR1:FLI1 fusion oncoprotein. Loss of DDX19A triggers marked global upregulation of transcription and chromatin...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $617,486 to ST Jude Children's Research Hospital Inc. on March 13, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The research investigates how chimeric transcription factors, specifically PAX3-FOXO1 and PAX7-FOXO1 fusion oncoproteins, suppress intrinsic innate immune responses in alveolar rhabdomyosarcoma (ARMS), an aggressive childhood soft...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $3,032,826 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective September 1, 2025, with a completion date of August 31, 2030. This award supports the FUSONC Program Project, which investigates fusion oncoproteins (FOPs)—abnormal proteins arising from gene translocations that drive approximately 17% of all cancers and are particularly...
- The National Institutes of Health National Cancer Institute awarded St Jude Children's Research Hospital Inc. $230,388 on January 12, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support a postdoctoral fellow studying transcription factor function in SWI/SNF-mutant rhabdoid tumors. The funded research elucidates the role of an essential transcription factor in rhabdoid tumors (RTs), rare pediatric cancers driven by SMARCB1 loss. The work leverages genome-wide CRISPR-CAS9...
- The National Cancer Institute awarded St Jude Children's Research Hospital Inc. $423,188 on July 17, 2026, under the Cancer Biology Research program (CFDA 93.396) to support a five-year project on compartmentalized branched-chain amino acid metabolism in myeloid leukemia. The award funds research investigating how BCAT1, a cytosolic enzyme catalyzing branched-chain amino acid metabolism, becomes aberrantly activated in acute myeloid leukemia and drives leukemogenesis through production of...